文献速递胸部肿瘤

帕博利珠单抗一线治疗PS 2晚期NSCLC的回顾性研究

First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
PubMed 文献 · Eur J Cancer · 2020-03-25

中位PFS 2.4个月,中位OS 3.0个月,6个月无进展率27%。因合并症导致PS 2者结局显著优于疾病负荷所致者,PS 2原因为唯一独立影响PFS和OS的因素。

要点

  • PS 2且PD-L1 TPS≥50%的NSCLC患者一线帕博利珠单抗总体结局不佳。
  • 因合并症导致PS 2者6个月无进展率49%,显著优于疾病负荷所致者的19%。
  • PS 2的原因是唯一独立影响PFS和OS的因素,未出现新的毒性问题。

核心结论

  • PS 2且PD-L1 TPS≥50%的晚期NSCLC患者接受一线帕博利珠单抗的结局总体不佳,但强烈依赖于导致PS 2的原因。

主要发现

  • 中位随访18.2个月,中位PFS为2.4个月(95%CI 1.6-2.5),中位OS为3.0个月(95%CI 2.4-3.5),6个月无进展率为27%(95%CI 21-35%)。
  • 因合并症导致PS 2者(n=41)对比疾病负荷所致PS 2者(n=112):6个月无进展率49% vs 19%,中位PFS 5.6 vs 1.8个月,中位OS 11.8 vs 2.8个月。
  • 帕博利珠单抗前接受放疗、抗生素或类固醇与临床结局相关。
  • PS 2的原因是唯一独立影响PFS和OS的因素。
  • 未出现毒性问题。

临床怎么用

  • 对PS 2且PD-L1 TPS≥50%的晚期NSCLC患者,一线帕博利珠单抗前应区分PS 2的原因,因合并症导致者可能获益更多。

局限性

  • 本研究为回顾性观察性研究,样本量有限,结果需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pembrolizumab is the first-line standard of care for advanced non-small cell lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS) ≥ 50%. Eastern Cooperative Oncology Group performance status (PS) 2 patients may receive pembrolizumab, despite the absence of sustaining evidence. PATIENTS AND METHODS: GOIRC-2018-01 is a multicentre, retrospective, observational study. PS 2 NSCLC patients with a PD-L1 TPS ≥50% receiving first-line pembrolizumab from June 2017 to December 2018 at 21 Italian institutions were included. Clinical-pathological characteristics were correlated with disease response and survival outcomes; adverse events were recorded. The primary objective was 6-months progression-free rate (6-months PFR). RESULTS: One hundred fifty-three patients (median age 70 years) were enrolled. At a median follow-up of 18.2 months, median progression-free survival (PFS) and overall survival (OS) were 2.4 (95% confidence interval, 95% CI, 1.6-2.5) and 3.0 months (95% CI 2.4-3.5), respectively. 6-months PFR was 27% (95% CI 21-35%). Patients with a PS 2 determined by comorbidities (n = 41) had significantly better outcomes compared with disease burden-induced PS 2 (n = 112). Indeed, 6-months PFR was 49% versus 19%, median PFS 5.6 versus 1.8 months and OS 11.8 versus 2.8 months, respectively. Additional potential prognostic factors (radiotherapy, antibiotics, steroids received before pembrolizumab) correlated with clinical outcomes. The determinant of PS 2 resulted the only factor independently impacting on both PFS and OS. No toxicity issues emerged. CONCLUSIONS: Outcomes of PS 2 NSCLC patients with PD-L1 TPS ≥50% receiving first-line pembrolizumab were globally dismal but strongly dependent on the reason conditioning the poor PS itself.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Facchinetti F, Mazzaschi G, Barbieri F, et al. First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. Eur J Cancer. 2020. PMID: 32220780. doi:10.1016/j.ejca.2020.02.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。